SEC Form 4 · accession 0001683168-17-001926
US-China Biomedical Technology, Inc. · UCBB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Michael R Dunn
Officer — CEO, CFO, President · Director · 10% Owner
Period of report
Jul 28, 2017
Accepted (ET)
Aug 2, 2017 · 1:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516079
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 28, 2017 | P | 3,500,000 | $0.033 | A | 3,500,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On June 28, 2017, Michael Dunn entered into a Stock Purchase Agreement with Goldenrise Development, Inc. (Goldenrise),whereby Dunn acquired from Goldenrise an aggregate 12,000,000 restricted common stock shares at a $0.033 cost basis per share. Concurrently, Dunn entered into a Stock Purchase Agreement with a secondary purchaser for the sale of 6,000,000 of the aggregate shares at a cost basis of $0.033, Dunn paid 1,500,000 shares to a consultant for services rendered; and distributed 1,000,000 to additional purchasers. The Closing of the sales occurred on July 28, 2017.